Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynsey Devlin

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Technical Innovations & Patient Support in Radiation Oncology|June 15, 2026
Radiation therapist research engagement and culture: findings from the ESTRO radiation therapist workshopYat Tsang, Siret Kivistik, Lynsey Devlin, et al.
Radiation Oncology (London, England)|August 27, 2021
Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
Radiation Oncology (London, England)|December 3, 2021
Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Technical Innovations & Patient Support in Radiation Oncology|June 15, 2026
Radiation therapist research engagement and culture: findings from the ESTRO radiation therapist workshopYat Tsang, Siret Kivistik, Lynsey Devlin, et al.
Radiation Oncology (London, England)|August 27, 2021
Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
Radiation Oncology (London, England)|December 3, 2021
Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
Pageof 2